期刊
CLINICAL ONCOLOGY
卷 25, 期 10, 页码 604-609出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.clon.2013.06.004
关键词
alpha Particles; beta electrons; radioimmunotherapy; targeted radiotherapy; vectors
类别
资金
- Cancer Research UK [11564] Funding Source: researchfish
- Cancer Research UK [A8993] Funding Source: Medline
This review highlights recent progress in the development of anticancer radiopharmaceuticals. Molecularly targeted radiotherapy refers to the selective delivery of radionuclides that emit charged particles, such as alpha particles, beta or Auger electrons, to cancer cells via a targeting vector. The discovery of new molecular targets through systems biology and other approaches has widened the scope for radiopharmaceutical development. Innovations in antibody engineering and humanisation, recombinant DNA technology, conjugation chemistry and, increasingly, nanotechnology have provided new approaches to the delivery of radionuclides to cancer cells. The increased availability of radioisotopes that have not traditionally been considered for therapy, such as alpha particle emitters, has also broadened the indications for targeted radiotherapy. (C) 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据